Pfizer Says Off-Label Marketing FCA Suit Falls Short

Law360, Los Angeles (January 16, 2013, 7:19 PM EST) -- Pfizer Inc. asked a Massachusetts federal court on Tuesday to dismiss a False Claims Act whistleblower suit alleging that it improperly promoted off-label use of a schizophrenia drug, saying that the plaintiffs have failed to show that the drugmaker actually defrauded federal health care programs.

In Tuesday's motion, Pfizer said that former employees Alex Booker and Edmund Hebron, who serve as relators in the 2010 suit filed on behalf of the U.S., 28 states and the District of Columbia, have now tried six times to craft...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.